Current | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000

Applera Corporation Announces Three Investor Relations Appointments

Norwalk, CT - July 23, 2001

Applera Corporation announced today that Peter Dworkin has been appointed vice president, investor relations for Applera Corporation, Robert M. Bennett has been appointed director, investor relations for its Celera Genomics Group (NYSE: CRA) and David Speechly, Ph.D., has been appointed to the new position of vice president, European corporate and financial communications for Applera Corporation.

Mr. Dworkin will have overall responsibility for the investor relations programs of the Corporation and will direct the investor relations program for the Applied Biosystems Group (NYSE:ABI). Mr. Bennett will direct the investor relations program for Celera. Dr. Speechly, based in London, will be the primary contact for European investors and media for Applied Biosystems and Celera Genomics. Mr. Dworkin and Mr. Bennett will be primary contacts for their respective groupís non-European investors.

Mr. Dworkin has more than 20 years of experience in investor relations, corporate communications and media. Prior to his new appointment, Mr. Dworkin was director, investor relations for Applied Biosystems since November 1999. He came to Applied Biosystems from Matrix Pharmaceutical, where he was senior director of investor relations and corporate communications. Prior to that he was with Protein Design Labs for four years as director, corporate communications. Mr. Dworkin also has held positions as a reporter for Fortune Magazine and the San Francisco Chronicle and served for four years with U.S. News and World Report as domestic correspondent and San Francisco bureau chief.

Mr. Dworkin has a BA in history from Brown University and a MBA from the Walter A. Haas School of Business at the University of California, Berkeley.

Previously, Mr. Bennett was director, investor relations for and prior to that served as director, investor relations for Witco Corporation and CK Witco Corporation. Before becoming an investor relations professional, Mr. Bennett held a series of increasingly responsible positions in marketing and sales management in the chemical industry.

Mr. Bennett has a BS degree in chemical engineering from Virginia Polytechnic Institute and an MBA degree in finance from the University of Michigan.

Dr Speechly joins Applera Corp from HCC De Facto in London, where he has served as Account Director leading activities in strategic corporate communications and investor relations specific to biotechnology and healthcare throughout Europe. Previously, he was an Account Manager at Noonan/Russo (London) where he represented bio-pharmaceutical clients listed on Nasdaq and pan-European exchanges.

Dr. Speechly has an MSc and PhD in Medicine from the University of Witwatersrand in Johannesburg, South Africa, and in 1999, was awarded an MBA from the Brookes School of Business, Oxford, United Kingdom.

About Applera Corporation
Applera Corporation comprises two operating groups. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA) and proteins to make scientific discoveries, leading to the development of new pharmaceuticals, and to conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.4 billion during fiscal 2000. The Celera Genomics Group, an integrated source of genomic and related medical information headquartered in Rockville, MD, is evolving to become a next generation therapeutic discovery company. Celera intends to leverage its industrialized approach to biology to develop platforms for enabling these new discoveries both for its own internal product development and for its customers, including collaboration partners and subscribers. Information about Applera Corporation, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the World Wide Web at, or by telephoning 800.762.6923.

Notice To Readers: Celera's press releases, presentations and printed remarks are included on this website for historical purposes only. The information contained in these documents should be considered accurate only as of the date of the relevant document. This information may change over time, and therefore visitors to this website should not assume that the information contained in these documents remains accurate at a later time. We do not have any current intention to update any of the information in these documents.